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Abstract
The Epstein-Barr virus (EBV) is a ubiquitous herpesvirus that transforms B cells and causes several malignancies
including Burkitt’s lymphoma. EBV differentially expresses at least 49 mature microRNAs (miRNAs) during latency in
various infected epithelial and B cells. Recent high-throughput studies and functional assays have begun to reveal the
function of the EBV miRNAs suggesting roles in latency, cell cycle control, and apoptosis. In particular, the central
executioner of apoptosis, Caspase 3 (CASP3), was proposed as a target of select EBV miRNAs. However, whether
CASP3 is truly a target of EBV miRNAs, and if so, which specific miRNAs target CASP3 is still under debate. Based on
previously published high-throughput biochemical data and a bioinformatic analysis of the entire CASP3 3′-UTR, we
identified 12 EBV miRNAs that have one or more seed binding sites in the CASP3 3′-UTR. We individually tested all 12
miRNAs for repression of CASP3 in luciferase reporter assays, and nine showed statistically significant (P < 0.001)
repression of a full-length CASP3 reporter. Further, three EBV miRNAs, including BART22, exhibited repression of
endogenous CASP3 protein. These data confirm that CASP3 is a direct target of specific EBV BART miRNAs.
Keywords: Epstein-Barr virus, microRNA, Caspase 3, Burkitt’s lymphoma
Abbreviations: EBV, Epstein-Barr virus; CASP3, Caspase 3; nt, nucleotide; 3′-UTR, 3′-untranslated region; BL, Burkitt’s
lymphoma; RISC, RNA-induced silencing complex; miRNA(s), microRNA(s); BART, BamHI A rightward transcripts

Background
Epstein-Barr virus (EBV; human herpesvirus 4) persists
in more than 95 % of the adult human population. Initial
EBV infection is either asymptomatic or manifests as
self-limiting mononucleosis. However, in a subset of
cases, EBV is also associated with the oncogenic transformation of cells, resulting in malignancies including
Burkitt’s lymphoma (BL) and several epithelial cell cancers (reviewed in [1]). After more than 50 years of study,
the role of EBV in cancer is still under investigation. In
addition to ~80 proteins and two ~170 nucleotide (nt)
noncoding RNAs, EBV differentially expresses at least 49
mature microRNAs (miRNAs) from 25 precursors [2–4].
MiRNAs are ~22 nt noncoding RNAs that direct the
modest downregulation of specific human and viral transcripts in diverse multicellular organisms. EBV miRNA
expression varies widely in different cell types, latency
stages, and strains of the virus [5, 6]. Select human
and EBV miRNAs are thought to contribute to the
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cancer phenotype in both lymphoid and epithelial
tumor types and are therefore considered possible
therapeutic targets [7–12].
EBV precursor miRNAs arise from two genomic clusters: three surrounding the BHRF1 gene (BHRF1-1, 1-2,
and 1-3), and 22 within the BART transcripts (BamHI A
rightward transcripts; BARTs1-22) [2]. The BARTs are
numbered in order of discovery and not in order of their
appearance in the EBV genome [2–4]. Most human and
viral miRNAs undergo a standard biogenesis pathway
beginning with RNA polymerase II transcription of the
primary-miRNA. In two steps, the first in the nucleus
and the second in the cytoplasm, RNAse III enzymes sequentially process the primary-miRNA into the intermediate precursor-miRNA hairpin and final mature
miRNA. One of the two strands is bound to core protein
Argonaute and a target mRNA within the RNA-induced
Silencing Complex (RISC). The single-stranded mature
miRNA directs RISC to specific mRNA targets, typically
via limited base-pairing to the mRNA 3′-untranslated
region (3′-UTR) [13]. Key to downregulation is the base
pairing interaction between the mRNA and 6-8 nt of the
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miRNA. This “seed region,” defined minimally as base
pairing including nts numbered 2-7 from the 5′ end of
the miRNA ([14]; Table 1), is crucial to the contacts between the miRNA, mRNA, and Argonaute protein [15].
Different patterns of base pairing can yield different degrees of repression; multiple sites are additive or synergistic, depending on their orientation [16]. Because the
function of a given miRNA is determined by the mRNAs
it targets, we and others conducted global biochemical
and bioinformatic analyses predicting interactions between EBV and human miRNAs and human transcripts
[11, 17, 18]. These studies provided thousands of predictions for miRNA-mRNA interactions, but further biochemical experimentation is required to confirm bona fide
interactions between EBV miRNAs and human transcripts.
Three types of studies have demonstrated the important and complex role of EBV miRNAs in apoptosis.
Phenotypic experiments implicated the BHRF1 miRNAs
in apoptotic inhibition and promotion of the cell cycle
during the early phase of infection of human primary B
cells [12, 19]. Expression of clusters of BART miRNAs
[20] or select BART miRNAs alone (BARTs 3, 6, 8, 16,
and 22; [11]) is sufficient to exert an anti-apoptotic
phenotype in AGS gastric carcinoma cells. Two different
high-throughput studies of EBV miRNA targeting
showed statistically significant enrichment of transcripts
associated with apoptosis in B cells infected with different strains of EBV [17, 18]. In our published study of
Jijoye cells [18], a BL cell line that expresses all known
EBV miRNAs, 1664 human 3′-UTRs were identified as
targets of the 12 most abundant EBV miRNAs, and approximately eight percent of these (132 transcripts) were
associated in some way with apoptosis. Direct targets of
EBV miRNAs were identified using standard reporter assays to validate base pairing between one or more EBV
miRNAs and mRNA targets, including pro-apoptotic
BBC3/PUMA [21], BCL2L11/BIM [20], BCL2L8/BAD
[22], and anti-apoptotic BID [8]. Thus, the BART miRNAs directly downregulate both pro-and anti-apoptotic
mediators that may vary by cell type.
Perhaps the most compelling mechanism for EBV
miRNA inhibition of apoptosis is the potential repression of Caspase 3 (CASP3), the central proteolytic executioner of apoptosis [23], first identified as a potential
direct EBV miRNA target in our high-throughput study
[18]. Multiple groups have attempted to illuminate the
role of EBV miRNAs in the regulation of CASP3. In an
indirect assay for CASP3 regulation by EBV miRNAs, B
cells infected by EBV lacking BART miRNAs expressed
higher CASP3 and were more resistant to mitochondriamediated apoptosis-inducing drugs relative to cells infected with intact EBV [24]. In a direct assay for miRNA
repression, slight (~20 %) repression of a CASP3-luciferase
reporter was observed after transfection of synthetic
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BARTs 1-3p and 16. Further, CASP3 protein levels decreased upon ectopic BART expression and increased
upon depletion of EBV from S1-1 BL cells [25]. However,
significant repression of a CASP3-luciferase reporter was
not observed for BARTs 3, 6, 8, 16, or 22, when each was
expressed from a lentiviral vector transfected into
HEK293T cells, in spite of seed sequence sites in the
CASP3 3′-UTR for each of these miRNAs [11]. Differences
in experimental approach have likely led to these inconsistent results. Regardless, other groups have found that
CASP3 protein is consistently lower in BL and epithelial
cells expressing clusters of the BART miRNAs relative to
cells without BARTs [20, 24, 25].
An individual study of each EBV miRNA with a potential binding site in CASP3 has not yet been undertaken,
so it is unclear if single EBV miRNAs directly target
CASP3. If single miRNAs are used as therapeutic targets, it is important to identify the unique targets/function of each. We employed systematic testing with
standard reporter assays and Western blots to address
our initial observation that CASP3 is a target of multiple
EBV BART miRNAs [18] and clarify the role of EBV
miRNAs in the regulation of CASP3. Nine EBV miRNAs
bind to 13 specific locations on the CASP3 3′-UTR;
three of the nine miRNAs detectably repress endogenous
CASP3 protein independently. This is a critical step in
detailing the mechanism by which EBV regulates apoptosis
and could provide clues for future rational drug design.

Methods
Bioinformatic analyses

Our previously published crosslinking and immunoprecipitation/high-throughput sequencing (HITS-CLIP) experiment identified CASP3 as a putative target of one or more
EBV miRNAs, but we had not examined the CASP3 3′UTR in single nucleotide resolution [18]. High-confidence
HITS-CLIP sequence fragments were mapped onto the human genome (hg 18) as in [18], and the UCSC Genome
Browser (https://genome.ucsc.edu) was used to generate an
image from our BED file to overlay with the 3′-UTR of
CASP3 (Fig. 1). The CASP3 3′-UTR was searched by hand
for the reverse complement of canonical seed binding sites
(7mer-A1, 7mer-m8, and 8mer) for all 49 known EBV miRNAs, and genomic coordinates of potential EBV miRNA
binding sites were confirmed using the BLAST-Like Alignment Tool (BLAT) on the UCSC Genome Browser (Fig. 1,
Table 1). All miRNA-mRNA pairs that met the minimal energetic requirements for base pairing were visualized using
RNA22 [26]. Sites of potential human miRNA seed binding
were identified by TargetScanHuman 7.0 [27].
Constructs

The full length 3′-UTR of CASP3 (hg18, Chr4:185785817185787419) was PCR amplified from genomic DNA and
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Table 1 Tested interactions between EBV miRNAs and the full-length CASP3 3’UTR

Human Caspase 3 3’UTR (chr4:184627696-184629271; GRCh38/hg38 assembly) was searched for seed base pairing (nt 2-7 highlighted in gray, A1 position underlined),
categorized by standard definitions [27]. “Non-canon” refers to the non-canonical site proposed by Veriede et al. [25]. All miRNA sequences are from MirBASE v. 21 [28].
Mutated sites in reporters are noted in bold lowercase letters
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500 bases
HITS-CLIP reads
CASP3 3’UTR
B3

B8A

B18A

B18B

B8B

B2B

EBV-miRNA sites
B4

B13 B7

B16 B10

B1 B20

B2A

B22A

B22B

hsa-miRNA sites
let-7

miR-138

Fig. 1 Caspase 3 has 16 predicted sites for EBV miRNA base pairing, 15 of which align with HITS-CLIP data. HITS-CLIP high-throughput sequencing
reads (0 or 1 mismatch; ≥25 nt long) from six biological replicates of Ago-bound RNAs in Jijoye BL cells (unique reads, one color per biological
replicate) mapped to scale on the Caspase 3 3′-UTR (1576 nt; RefSeq ID: NM_004346.3). Predicted sites of miRNA seed sequence binding for EBV
miRNAs (black) and human miRNAs (purple) are noted below, with non-verifiable EBV miRNA sites in gray. When two sites for a given miRNA are
present, they are labeled “A” and “B” from 5′ to 3′, respectively. Sites for BARTs 4, 7, and 22B met our initial HITS-CLIP reproducibility thresholds
(three or more experimental replicates, peak height of five or more; [18])

inserted downstream of firefly luciferase between NheI
and XhoI in the pmiRGLO dual luciferase vector (Promega; Additional file 1: Table S1). Mutants were generated by site-directed mutagenesis (Stratagene) at the
positions indicated in Table 1 with primers provided in
Additional file 1: Table S1. All plasmids were verified
by sequencing (Eurofins Genomics). Synthetic miRNAs
(IDT) were synthesized according to the mature
miRNA sequences in miRBase 21 [28] with a 5′-phosphate on the functional strand only, a mismatch at nt 2,
and 2-nt 3′ overhangs, as in previous studies [14, 18, 29].
Pairs were annealed and confirmed on 3 % agarose gels
according to [30]. The control miRNA “CTL” (5′-CTAGT
ATGACTAGTATGATCCGG top strand) has been used
in previous studies [18]. CTL is a scrambled sequence
with the same proportion of each nucleotide as hsa-miR17, and it has no known biological function, seed sequence
similarity to a known viral/human miRNA, or canonical
targeting of CASP3.
Luciferase assays

HEK293T cells (ATCC) in 24-well plates were cotransfected with 40 nM synthetic miRNA duplex and 2.5
ng pmiRGLO reporter plasmid using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions. Cells were lysed 24 h post-transfection, and
the Dual-Luciferase Assay Reporter System (Promega)
manufacturer’s protocol was performed with the GloMax
Junior Luminometer (Promega). Firefly luciferase activity
was normalized to the control Renilla luciferase activity in
each well, and this ratio was then normalized to the control construct appropriate for each experiment. At least
four independent transfections for each condition were
measured. Excel was used to calculate the standard deviation for each data point, and two-tailed Student’s t-tests
were used to compare samples as noted.
Western blots

HEK293T cells were transfected in triplicate with the denoted synthetic miRNAs (40 nM) in the figures using Lipofectamine 2000 (Invitrogen). Protein lysates were

prepared from cells, and Western blot analyses were performed as described (Wade and Allday, 2000) using
NuPAGE 4-12 % gels and associated buffers (Invitrogen).
Primary antibodies were anti-Caspase 3 (8G10; #9665)
and anti-alpha-tubulin #2125 (Cell Signaling Technology).
Western blots were quantified using ImageQuant software, with CASP3 levels normalized to the tubulin loading
controls and these values normalized to the control transfection condition.

Results
Argonaute HITS-CLIP experiments yield genome-wide
maps of likely Argonaute and miRNA binding. Our previous HITS-CLIP data revealed potential interactions between EBV miRNAs and 132 host apoptotic mRNAs,
including CASP3 [18]. We examined CASP3 because of
its central role in apoptosis and the high reproducibility of
the HITS-CLIP sequencing tags—sites of Argonaute binding—that overlapped with predicted seed binding sites
for BARTs 4, 7, and 22 (Fig. 1). Because our HITS-CLIP
experiment was performed in BL cells expressing all EBV
miRNAs to varying degrees, we conducted a bioinformatic
search for binding sites for all 49 EBV miRNAs and uncovered six more EBV miRNAs with one or more binding
sites as well as a possible site for BART20 that did not
overlap with our HITS-CLIP Argonaute binding sites
(Fig. 1). In total, there are 14 putative miRNA binding
sites for nine EBV miRNAs on the CASP3 3′-UTR. We
also included two non-canonical sites for comparison: the
previously published BART16 [25], which has a wobble
base pair in the seed, and BART10, which has a 6mer site
predicted in CASP3 (Fig. 1, Table 1).
In order to validate the bioinformatic and HITS-CLIP
predicted interactions, the full-length 3′-UTR of CASP3
was cloned into a dual-luciferase reporter vector and cotransfected into HEK293T cells with individual synthetic
miRNAs. Significant repression of the full-length CASP3
3′-UTR reporter occurred after transfection of synthetic
BART 4, 3, 13, 8, 7, 18, 1, 2, or 22 (Fig. 2a). BART22 incited the greatest repression, and BARTs 16, 10, and 20
did not detectably repress CASP3.
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Fig. 2 EBV miRNAs repress a full-length luciferase-Caspase 3 3′-UTR reporter. HEK293T cells were co-transfected with the designated luciferase-Caspase
3 reporters and either total synthetic control miRNA duplex (CTL) or an EBV miRNA predicted to base pair with the Caspase 3′-UTR (Table 1 includes all
WT and mutant sequences). Firefly/Renilla luciferase ratios were normalized to the same reporter transfected with the negative control miRNA (CTL). a
Wild type (WT) Caspase 3 is repressed significantly by nine EBV miRNAs. b WT repression is compared to loss of repression of the relevant mutant for
each of the miRNAs that showed the greatest WT repression. In all luciferase assays, mean values were from at least four independent transfections.
Error bars, standard deviation; P values from two-tailed Student’s t-tests of noted pairs, *P < 0.0001, **P < 0.01

The specificity of downregulation by CASP3 at the
each of the most statistically significant and repressed
(>20 %) binding sites was further confirmed by comparing wild-type 3′-UTR repression to the repression of a
corresponding reporter with 2-3 point mutations in each
seed binding region (Fig. 2b, Table 1). Three of the miRNAs that showed significant repression each had two
possible sites (Fig. 1), so we individually mutated each
site. The HITS-CLIP data show far less Argonaute binding at the BART8A, BART2A, and BART22A sites relative to their partner B sites (Fig. 1). In the case of
BART2, the “B” site appeared to be more functional than
the A. Mutation of the BART 22 “A” site alone was sufficient to de-repress the reporter almost completely
(Fig. 2b), but mutation of the “B” site also showed significant derepression, suggesting that these two sites

may work synergistically even though they are 312 nt
apart (Table 1), because loss of either single site eliminates repression. In contrast, the weak BART8 repression via two sites appears to be roughly equal and
additive (Fig. 2b). In total, our luciferase assay validates
direct, reproducible, varying repression of the CASP3
3′-UTR reporter by BARTs 4, 3, 13, 8, 7, 1, 2, and 22.
Given that these miRNAs significantly repress protein
made from a reporter construct, we hypothesized that
we might also see an effect on endogenous levels of
CASP3 protein. Thus, we transfected individual synthetic EBV miRNAs into HEK293T cells, which lack endogenous EBV miRNAs, to confirm downregulation of
endogenous CASP3 protein by Western blotting. CASP3
was downregulated most significantly by BART22 but
also weakly by BARTs 8, 7, 1, and 2 (Fig. 3).
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Fig. 3 Select EBV miRNAs repress endogenous Caspase 3 protein.
HEK293T cells were transfected with the denoted control or EBV
miRNA. Western blots of extracts prepared 24 h post-transfection
were probed for endogenous proteins with anti-Caspase 3 or
anti-tubulin antibodies. Normalized CASP3 levels from triplicate
experiments are reported below with the S.E.M

Discussion
In the time since the publication of our high-throughput
experiment that proposed CASP3 as a target of EBV
miRNAs, several groups have published conflicting evidence of this interaction [11, 18, 22, 24, 25]. Here we
confirmed that human CASP3 is a direct target of nine
EBV BART miRNAs in luciferase assays by testing all canonical, predicted sites. Three of these miRNAs detectably, independently repressed endogenous CASP3 in
HEK293T cells.
To complement our reporter assays, we used high levels
of individual synthetic EBV miRNAs to demonstrate detectable repression of endogenous CASP3 protein on the
part of select EBV miRNAs (Fig. 3). The levels of miRNA
used in this proof-of-principle experiment are probably
not physiologically attainable, but others have documented the effect of EBV miRNA expression on CASP3
protein levels and downstream effects on its substrate
PARP (a measure of CASP3 activity) in both B cells and
epithelial cells that are models for EBV infection. For example, CASP3 and cleaved PARP increase when AGS epithelial cells are treated with an inhibitor of BART20-5p.
While BART20-5p is not likely a direct repressor of the
CASP3 transcript, it represses BAD, a pro-apoptotic protein upstream of CASP3 [22]. Similarly, in EBV-infected B
cells, CASP3 protein increases when all of the BARTs are
deleted from the M81 strain [24]. Because the BART miRNAs target so many apoptotic transcripts [11, 17, 18], the
effect of each individual EBV miRNA on CASP3 protein
levels may vary. Thus, the luciferase assay is perhaps the
best way to probe direct targeting of a given transcript.
The dual luciferase reporter assay undertaken in a cell
line lacking relevant endogenous miRNAs remains the
gold standard in the validation of direct targeting by
miRNAs. Kang et al. (2015) recently conducted a reporter assay experiment similar to ours but only tested
five miRNAs that had exerted an anti-apoptotic phenotype when expressed alone in their epithelial (gastric carcinoma) cell model (BARTs 3, 6, 8, 16, 22). The authors
concluded that none of these miRNAs significantly repressed their CASP3 luciferase reporter in HEK293T

cells. This conclusion may be explained by two key differences in our experimental designs: (1) the differing
identity of our negative controls, and (2) the origin of
our miRNAs. Cognizant that ectopic expression/transfection of both miRNAs and luciferase reporters skews
the natural stoichiometry within a cell [31], and synthetic miRNAs accumulate well above physiologically attainable levels [32], all of our data are normalized to
repression by a equal amounts of a transfected synthetic
miRNA that does not repress our target of interest rather than a “mock” or “empty vector” transfection. Our
synthetic miRNA duplexes may have accumulated to
higher levels relative to the reporter than the miRNAs
expressed from transduced lentiviral vectors employed
by Kang et al, since those miRNAs presumably required
standard biogenesis processing.
The BART miRNAs are expressed together in large
clusters and likely operate in tandem [3, 19, 33]. Multiple
miRNA binding sites in a single 3′-UTR are additive, so
major targets of EBV miRNAs would have several miRNA
binding sites, as appears to be the case for CASP3. Indeed,
expression of BART miRNA clusters in B cells and AGS
epithelial cells correlates with CASP3 depletion [20, 24]. If
miRNA seed binding sites are 8 ~ 40 nt separated, repression is likely synergistic [14]. In CASP3 we noted one such
potential case: the seed site for BART4 is 10 nt away from
the seed site for human miRNA let-7. Further, while not
highly expressed, let-7 is present in EBV+ Jijoye cells at
approximately the same level as EBV-miR-BART5 or
BART20-3p [18]. Human and viral miRNAs have been
previously shown to co-target transcripts [17, 18], and it is
possible that the effectiveness of BART4 repression is enhanced by its proximity to the let-7 site. TargetScan
Human identified one other conserved but weaker potential binding site for a human miRNA: hsa-miR-138 (Fig. 1)
[27]. MiR-138 is expressed at levels comparable to BART5
and let-7 in Jijoye cells [18], but our HITS-CLIP data do
not overlap with this site, and no others have validated its
direct regulation of CASP3. Consistent with this is the recent finding that miR-138 inhibits TNF-α-induced apoptosis in the human intervertebral disc, where an inhibitor
of miR-138 dramatically suppressed the expression of
cleaved CASP3 [34].
A previous study showed downregulation of CASP3 by
BARTs 1-3p and 16 [25]. While our luciferase assay
showed CASP3 repression upon treatment with BART1,
we, like others [11], were unable to confirm their findings in the case of BART16. This is probably explained
by the absence of true seed binding sites for BART16.
The potential binding sites on the 3′-UTR of CASP3
contain a non-canonical Watson-Crick base pair in one
nucleotide position of the seed region (Table 1). Noncanonical binding has been reported between human
miRNAs and mRNAs, including seed regions binding
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with a G:U wobble base; however, the repression by
these sites are not as significant as that of canonical sites
[35, 36]. Similarly, the weaker 6mer site for BART10 did
not exhibit repression of CASP3. Interestingly, the bioinformatically predicted site for BART20 was not validated
by either HITS-CLIP data nor luciferase assays in spite
of a predicted 7mer-A1 binding site, underscoring the
need to move beyond bioinformatic predictions into the
realm of biochemical testing before drawing conclusions.
Kaposi’s sarcoma herpesvirus (KSHV), a human gammaherpesvirus responsible for primary effusion lymphoma
(PEL) and Kaposi’s sarcoma (KS), also expresses miRNAs
that repress apoptotic targets including CASP3 [37, 38].
Though KSHV and EBV miRNA sequences are not conserved and show functional differences with respect to the
latent-to-lytic switch, targeting the same apoptotic transcript potentially shows a similar method for controlling
apoptosis in the two viruses [39, 40].
A decrease in apoptotic activity of EBV-positive cells
could promote malignancy in conjunction with the deactivation of other important cellular pathways by EBV
miRNAs. The 100+ other apoptotic transcripts with putative EBV miRNA binding sites should be studied to
elucidate the mechanism by which EBV controls host
cell apoptosis and further our understanding of how the
virus causes malignancy. While the EBV BART miRNAs
work in tandem to repress CASP3, therapeutically targeting a large number of miRNAs is likely more challenging and may have more off-target consequences.
Knowing that single miRNAs can repress a key target
may help us better conduct future rational drug design
regarding EBV and BL.
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